Our mechanism derived biomarkers (HIF-1α and galectin-3) suggest the evaluation of Hsp90 inhibitors in pancreatic cancer, and not just in kinase-addicted cancers. This evidence concerns the gene HIF1A and familial pancreatic carcinoma.